Properties (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
fertility medication
|
| gptkbp:activeDuring |
follicle-stimulating hormone
luteinizing hormone |
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:clinicalTrials |
Phase III
assisted reproductive technology ESHRE guidelines ASRM_guidelines |
| gptkbp:commonName |
150 IU
225 IU 75 IU |
| gptkbp:compatibleWith |
calcium solutions
dextrose solutions |
| gptkbp:contains |
menotropins
|
| gptkbp:contraindication |
pregnancy
allergy to menotropins tumors of the pituitary gland uncontrolled thyroid disease |
| gptkbp:dosageForm |
lyophilized powder
|
| gptkbp:drugInterdiction |
true
gonadotropins |
| gptkbp:healthcare |
storage instructions
hormone levels ultrasound examinations injection technique side effects awareness |
| https://www.w3.org/2000/01/rdf-schema#label |
Menopur
|
| gptkbp:inventorResidence |
sterile water
|
| gptkbp:isDividedInto |
anticoagulants
hormonal contraceptives other fertility medications |
| gptkbp:isReflectedIn |
true
|
| gptkbp:issuedBy |
subcutaneous injection
|
| gptkbp:lastProduced |
2000
|
| gptkbp:marketedAs |
gptkb:Menopur
|
| gptkbp:offersCoursesIn |
gptkb:Australia
gptkb:Canada gptkb:UK gptkb:USA |
| gptkbp:packaging |
vials
|
| gptkbp:producedBy |
gptkb:Ferring_Pharmaceuticals
|
| gptkbp:provides |
in vitro fertilization
|
| gptkbp:route |
subcutaneous
|
| gptkbp:shelfLife |
24 months
|
| gptkbp:sideEffect |
headache
nausea abdominal pain ovarian hyperstimulation syndrome |
| gptkbp:storage |
refrigerated
|
| gptkbp:triggerType |
stimulates ovarian follicle development
|
| gptkbp:usedFor |
ovarian stimulation
|